Emavusertib

Curis Inc. announced encouraging outcomes from its TakeAim Leukemia study for Acute Myeloid Leukemia treatment with emavusertib, achieving 10 objective responses among 19 evaluable patients. The company faces profitability challenges but sees potential in emavusertib's novel mechanism and broader development program, including Orphan Drug Designations. Curis projects confidence in emavusertib's prospects despite development risks and undervalued stock.

Curis, Inc. will report Q3 2024 financial and operating results on Nov. 14, 2024, at 8:00 a.m. ET, followed by a conference call and webcast at 8:30 a.m. ET. Curis focuses on developing emavusertib, an orally available, small molecule IRAK4 inhibitor, currently in Phase 1/2 studies for various cancers.

The TakeAim Lymphoma trial (NCT03328078) combines emavusertib and ibrutinib to treat relapsed or refractory primary central nervous system lymphoma (PCNSL), addressing limited treatment options. Early results show promising responses, including complete responses in BTK inhibitor-refractory patients, highlighting the potential of dual IRAK4 and BTK inhibition. Challenges include PCNSL's rarity and patient disengagement post-relapse. Positive trial results could advance emavusertib's development and expand its use in other B-cell malignancies refractory to BTK inhibitors.

Emavusertib (CA-4948) combination therapy shows promise in refractory primary central nervous system lymphoma (PCNSL) patients, with responses observed in those resistant to BTK inhibitors. The ongoing TakeAim Lymphoma trial (NCT03328078) is currently enrolling relapsed/refractory patients for its expansion cohort, which will test the combination regimen. Exciting data from this cohort is expected to be presented at the 2024 ASH Annual Meeting.